VLP Therapeutics, headquartered in Gaithersburg, Maryland, is at the forefront of developing next-generation vaccine technology aimed at combating epidemic and pandemic diseases. The company specializes in creating self-amplifying RNA vaccines, which have shown promising results in clinical trials, including a Phase 3 trial targeting the Omicron XBB variant of COVID-19. VLP Therapeutics serves global healthcare markets, focusing on diseases that currently lack effective treatments. The business model revolves around research and development, clinical trials, and eventual commercialization of their vaccine technologies. Revenue is generated through partnerships, grants, and future sales of approved vaccines. The company aims to make significant contributions to global public health by eradicating diseases through innovative vaccine solutions.

Keywords: vaccine technology, self-amplifying RNA, clinical trials, COVID-19, Omicron XBB, global health, epidemic diseases, pandemic solutions, biotechnology, immunogenicity.